Prices Of Formulations Set To Increase From April

New Delhi : Prices of essential medicines – including painkillers, anti-infectives, cardiac drugs and antibiotics – are slated to go up from April, dealing a body blow to consumers already reeling under the impact of inflation.

The government is all set to allow drug companies an increase in line with the change in the annual Wholesale Price Index (WPI). The annual change in WPI, as notified by the government, works out to 12.12% during 2022, the drug prices regulator National Pharmaceutical Pricing Authority (NPPA) said on Monday.

Prices of 384 molecules, which correspond to around 900 formulations across 27 therapies, are expected to go up by over 12%. This is the second year in a row when the increase is more than that allowed for non-scheduled drugs. The 384 molecules, part of the national list of essential medicines, are also known as scheduled drugs, with their prices regulated by the NPPA.

The rest – non-scheduled drugs which are outside price control – are allowed an annual increase of 10% every year. For the year 2021, the subsequent hike in drugs was over 10% in line with change in WPI.

Historically, the increase in prices due to the annual change in WPI has been marginal, ranging between 1% and 2% over the last few years. The NPPA will notify the ceiling prices of the scheduled formulations over the next few days, sources said.

The development will be welcome news for the industry, which has been battling a surge in manufacturing costs on account of multiple factors. During pandemic, the industry was impacted by a rise in prices of raw materials (active pharmaceutical ingredients), freight and increase in plastics and packaging material, among other costs.

“The industry will be relieved once the new prices are notified. It has been facing a cost escalation due to imported raw materials and excipients in certain drugs. Also, it will be a relief for those drugs which were added to the scheduled drugs’ list,” an industry expert said.

  • Related Posts

    CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

    The Central Drugs Standard Control Organisation (CDSCO) found one spurious and 220 not of standard quality (NSQ) drug samples from a batch tested randomly as part of the August drug…

    FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot

    The action follows the department’s investigation into a large-scale unlicenced drug repacking and relabelling racket uncovered at a farmhouse in Bengaluru South district’s Bidadi on August 18. The Karnataka Food…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

    CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

    FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot

    FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot

    Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

    Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

    WHO launches new primary health care course to strengthen health systems globally

    WHO launches new primary health care course to strengthen health systems globally

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman